Metrics
11 Record Views
- Title
- Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types
- Creators
- Komal L Jhaveri - Memorial Sloan Kettering Cancer Center, New York, NYPhilippe L Bedard - Princess Margaret Cancer Centre, Toronto, ON, CanadaJuan Miguel Cejalvo - Biomedical Research Institute INCLIVA, Valencia, SpainLowell L Hart - Florida Cancer Specialists/SCRI, Fort Myers, FLDejan Juric - Massachusetts General Hospital Cancer Center, Boston, MAKaren Kelly - UC Davis Comprehensive Cancer Center, Sacramento, CAA. Craig Lockhart - Washington University School of Medicine, St Louis, MOAnton Melnyk - Texas Cancer Center, Abilene, TXKathleen N Moore - Stephenson Oklahoma Cancer Center, Oklahoma City, OKJohn J Nemunaitis - Mary Crowley Cancer Research Center, Dallas, TXMafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, SpainManish R Patel - Florida Cancer Specialists and Research Institute, Sarasota, FLJasgit Sachdev - Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZDavid Smith - Compass Oncology, Vancouver, WAAri VanderWalde - University of Tennessee West Cancer Center, Memphis, TNJoseph A Ware - Genentech, Inc., South San Francisco, CAHuan Jin - Genentech, Inc., South San Francisco, CATimothy R Wilson - Genentech, Inc., South San Francisco, CAMichael C Wei - Genentech, Inc., South San Francisco, CAJose Baselga - Memorial Sloan Kettering Cancer Center, New York, NY
- Publication Details
- Journal of clinical oncology, Vol.34(15_suppl), pp.TPS11621-TPS11621
- Academic Unit
- Miller School of Medicine
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031599450402976